Publications: Craig Horbinski
Download CSV for Craig Horbinski
| Title | Year | Citations | Score |
|---|---|---|---|
|
Epidemiologic and molecular prognostic review of glioblastoma
Cancer epidemiology, biomarkers & prevention 23 (10), 1985-1996, 2014 View Details |
2014 | 1628 | 99.2% |
|
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-oncology 22 (8), 1073-1113, 2020 View Details |
2020 | 630 | 98.8% |
|
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Nature medicine 25 (3), 462-469, 2019 View Details |
2019 | 620 | 98.5% |
|
Glioma progression is shaped by genetic evolution and microenvironment interactions
Cell 185 (12), 2184-2199. e16, 2022 View Details |
2022 | 158 | 97.6% |
|
Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology
Journal of the National Comprehensive Cancer Network 18 (11), 1537-1570, 2020 View Details |
2020 | 302 | 97.0% |
|
CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells
Cancer research 76 (19), 5671-5682, 2016 View Details |
2016 | 510 | 96.8% |
|
An overview of meningiomas
Future Oncology 14 (21), 2161-2177, 2018 View Details |
2018 | 419 | 96.6% |
|
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
Nature Reviews Neurology 18 (9), 515-529, 2022 View Details |
2022 | 107 | 96.0% |
|
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Nature medicine 23 (4), 493-500, 2017 View Details |
2017 | 360 | 95.5% |
|
A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
Science translational medicine 13 (584), eabb3945, 2021 View Details |
2021 | 142 | 95.0% |
|
Musculoskeletal involvement of COVID-19: review of imaging
Skeletal radiology 50, 1763-1773, 2021 View Details |
2021 | 142 | 95.0% |
|
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes
Nature medicine 26 (7), 1044-1047, 2020 View Details |
2020 | 195 | 94.8% |
|
Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death
The American journal of pathology 170 (1), 75-86, 2007 View Details |
2007 | 520 | 94.6% |
|
Mitochondrial control by DRP1 in brain tumor initiating cells
Nature neuroscience 18 (4), 501-510, 2015 View Details |
2015 | 350 | 94.6% |
|
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Neuro-oncology 25 (1), 4-25, 2023 View Details |
2023 | 46 | 93.9% |
|
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
Neuro-oncology 21 (7), 901-910, 2019 View Details |
2019 | 193 | 93.5% |
|
Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress
Cell metabolism 32 (2), 229-242. e8, 2020 View Details |
2020 | 163 | 93.5% |
|
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer
Cancer research 70 (20), 7992-8002, 2010 View Details |
2010 | 407 | 93.3% |
|
NCCN guidelines® insights: central nervous system cancers, version 2.2022: featured updates to the NCCN guidelines
Journal of the National Comprehensive Cancer Network 21 (1), 12-20, 2023 View Details |
2023 | 42 | 93.3% |
|
Preferential iron trafficking characterizes glioblastoma stem-like cells
Cancer cell 28 (4), 441-455, 2015 View Details |
2015 | 276 | 92.8% |
|
Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner
Cancer discovery 10 (8), 1210-1225, 2020 View Details |
2020 | 149 | 92.8% |
|
Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1–mediated lipogenesis
Clinical Cancer Research 22 (21), 5337-5348, 2016 View Details |
2016 | 243 | 92.4% |
|
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
The Lancet Oncology 22 (8), 1103-1114, 2021 View Details |
2021 | 95 | 91.9% |
|
DMT1: a mammalian transporter for multiple metals
Biometals 16, 41-54, 2003 View Details |
2003 | 428 | 91.4% |
|
Mutant IDH1 and seizures in patients with glioma
Neurology 88 (19), 1805-1813, 2017 View Details |
2017 | 196 | 91.0% |
|
MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radioresistance in glioblastoma
Cancer cell 32 (6), 840-855. e8, 2017 View Details |
2017 | 193 | 90.9% |
|
Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation
Cell reports 19 (9), 1858-1873, 2017 View Details |
2017 | 192 | 90.8% |
|
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Nature 547 (7663), 355-359, 2017 View Details |
2017 | 192 | 90.8% |
|
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome
Acta neuropathologica 134, 705-714, 2017 View Details |
2017 | 191 | 90.8% |
|
Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth
Clinical Cancer Research 25 (12), 3643-3657, 2019 View Details |
2019 | 139 | 90.5% |
|
Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression
Stem cells 32 (7), 1746-1758, 2014 View Details |
2014 | 222 | 90.1% |
|
Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations
Clinical cancer research 26 (2), 477-486, 2020 View Details |
2020 | 107 | 89.6% |
|
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma
Acta neuropathologica communications 5, 1-12, 2017 View Details |
2017 | 169 | 89.4% |
|
The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma
Science translational medicine 7 (304), 304ra143-304ra143, 2015 View Details |
2015 | 195 | 89.2% |
|
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
Acta Neuropathologica Communications 8, 1-14, 2020 View Details |
2020 | 98 | 88.4% |
|
Molecular and translational advances in meningiomas
Neuro-oncology 21 (Supplement_1), i4-i17, 2019 View Details |
2019 | 116 | 88.4% |
|
Kinase signaling cascades in the mitochondrion: a matter of life or death
Free Radical Biology and Medicine 38 (1), 2-11, 2005 View Details |
2005 | 280 | 88.0% |
|
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma
Nature cell biology 21 (8), 1003-1014, 2019 View Details |
2019 | 111 | 87.8% |
|
What do we know about IDH1/2 mutations so far, and how do we use it?
Acta neuropathologica 125, 621-636, 2013 View Details |
2013 | 194 | 87.5% |
|
Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival
Clinical Cancer Research 23 (21), 6650-6660, 2017 View Details |
2017 | 141 | 87.1% |
|
Myeloid-derived suppressive cells promote B cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma
Cancer immunology research 7 (12), 1928-1943, 2019 View Details |
2019 | 104 | 87.0% |
|
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
Neuro-oncology 20 (7), 873-884, 2018 View Details |
2018 | 123 | 86.3% |
|
Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma
Journal of Controlled Release 223, 75-84, 2016 View Details |
2016 | 143 | 86.3% |
|
Mutant IDH1 and thrombosis in gliomas
Acta neuropathologica 132, 917-930, 2016 View Details |
2016 | 143 | 86.3% |
|
NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data
Nucleic acids research 44 (20), e151-e151, 2016 View Details |
2016 | 137 | 85.6% |
|
A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma
Journal of Neuropathology & Experimental Neurology 77 (11), 1039-1054, 2018 View Details |
2018 | 113 | 85.2% |
|
PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells
Molecular cell 81 (6), 1276-1291. e9, 2021 View Details |
2021 | 55 | 84.9% |
|
Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth
Nature Metabolism 4 (5), 575-588, 2022 View Details |
2022 | 34 | 84.8% |
|
NAD+ regeneration rescues lifespan, but not ataxia, in a mouse model of brain mitochondrial complex I dysfunction
Cell metabolism 32 (2), 301-308. e6, 2020 View Details |
2020 | 75 | 84.6% |
|
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas
Neuro-oncology 22 (4), 470-479, 2020 View Details |
2020 | 71 | 83.7% |
|
Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma
Clinical cancer research 27 (23), 6514-6528, 2021 View Details |
2021 | 51 | 83.6% |
|
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
Journal of Neuropathology & Experimental Neurology 68 (12), 1319-1325, 2009 View Details |
2009 | 181 | 83.5% |
|
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
Neuro-oncology 14 (6), 777-789, 2012 View Details |
2012 | 158 | 83.5% |
|
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
Neuro-oncology 18 (11), 1519-1528, 2016 View Details |
2016 | 118 | 83.2% |
|
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas
Acta neuropathologica 119, 641-649, 2010 View Details |
2010 | 171 | 82.5% |
|
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors
Neuro-oncology 18 (3), 379-387, 2015 View Details |
2015 | 124 | 82.5% |
|
SRSF3-regulated RNA alternative splicing promotes glioblastoma tumorigenicity by affecting multiple cellular processes
Cancer research 79 (20), 5288-5301, 2019 View Details |
2019 | 75 | 81.6% |
|
Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma
Clinical Cancer Research 26 (19), 5232-5245, 2020 View Details |
2020 | 63 | 81.6% |
|
Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma
Science Advances 7 (8), eabc8929, 2021 View Details |
2021 | 45 | 81.3% |
|
To BRAF or Not to BRAF: Is That Even a Question Anymore?
Journal of Neuropathology & Experimental Neurology 72 (1), 2-7, 2013 View Details |
2013 | 128 | 80.8% |
|
Major features of the 2021 WHO classification of CNS tumors
Neurotherapeutics 19 (6), 1691-1704, 2022 View Details |
2022 | 26 | 79.9% |
|
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma
Cell death & disease 10 (4), 292, 2019 View Details |
2019 | 68 | 79.8% |
|
Beyond thrombosis: the impact of tissue factor signaling in cancer
Journal of Hematology & Oncology 13, 1-14, 2020 View Details |
2020 | 57 | 79.7% |
|
Glioblastoma as an age-related neurological disorder in adults
Neuro-oncology advances 3 (1), vdab125, 2021 View Details |
2021 | 41 | 79.5% |
|
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Nature cancer 2 (12), 1372-1386, 2021 View Details |
2021 | 41 | 79.5% |
|
Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma
Clinical Cancer Research 27 (6), 1766-1777, 2021 View Details |
2021 | 40 | 79.0% |
|
IDH3α regulates one-carbon metabolism in glioblastoma
Science advances 5 (1), eaat0456, 2019 View Details |
2019 | 65 | 78.9% |
|
RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
Oncotarget 6 (17), 14766, 2015 View Details |
2015 | 99 | 78.2% |
|
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma
Brain 144 (4), 1230-1246, 2021 View Details |
2021 | 37 | 77.4% |
|
Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer
Cancer research 74 (8), 2362-2373, 2014 View Details |
2014 | 100 | 77.1% |
|
PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma
Brain pathology 23 (5), 565-573, 2013 View Details |
2013 | 105 | 76.9% |
|
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma
Neuro-oncology 16 (11), 1478-1483, 2014 View Details |
2014 | 99 | 76.9% |
|
A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways
Nature communications 7 (1), 12885, 2016 View Details |
2016 | 82 | 75.9% |
|
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients
Neuro-oncology 21 (12), 1498-1508, 2019 View Details |
2019 | 55 | 75.2% |
|
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
Journal for immunotherapy of cancer 11 (2), 2023 View Details |
2023 | 12 | 75.0% |
|
Phase II study of nonmetastatic desmoplastic medulloblastoma in children younger than 4 years of age: a report of the Children’s Oncology Group (ACNS1221)
Journal of Clinical Oncology 38 (3), 223, 2020 View Details |
2020 | 46 | 75.0% |
|
Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade
Brain pathology 21 (1), 57-73, 2011 View Details |
2011 | 104 | 74.3% |
|
Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
Journal of Experimental Medicine 218 (1), e20200913, 2020 View Details |
2020 | 44 | 74.0% |
|
Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies
The Journal of Molecular Diagnostics 12 (4), 487-492, 2010 View Details |
2010 | 109 | 74.0% |
|
Live free or die: tales of homeless (cells) in cancer
The American journal of pathology 177 (3), 1044-1052, 2010 View Details |
2010 | 109 | 74.0% |
|
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
Scientific reports 9 (1), 8946, 2019 View Details |
2019 | 52 | 73.9% |
|
Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer
Cancer research 76 (4), 912-926, 2016 View Details |
2016 | 75 | 73.8% |
|
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology
Acta neuropathologica 127, 825-843, 2014 View Details |
2014 | 84 | 73.1% |
|
Mechanisms of manganese-induced rat pheochromocytoma (PC12) cell death and cell differentiation
Neurotoxicology 23 (2), 147-157, 2002 View Details |
2002 | 119 | 72.6% |
|
6-Hydroxydopamine induces mitochondrial ERK activation
Free Radical Biology and Medicine 43 (3), 372-383, 2007 View Details |
2007 | 105 | 72.1% |
|
Autophagy and oxidative stress in gliomas with IDH1 mutations
Acta neuropathologica 127, 221-233, 2014 View Details |
2014 | 79 | 71.6% |
|
PARP-1 regulates epithelial–mesenchymal transition (EMT) in prostate tumorigenesis
Carcinogenesis 35 (11), 2592-2601, 2014 View Details |
2014 | 78 | 71.3% |
|
Differential localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells
Journal of Neuroscience 20 (20), 7595-7601, 2000 View Details |
2000 | 111 | 70.6% |
|
Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas
Brain pathology 21 (5), 564-574, 2011 View Details |
2011 | 87 | 70.3% |
|
Toward a standard pathological and molecular characterization of recurrent glioma in adults: a response assessment in neuro-oncology effort
Neuro-oncology 22 (4), 450-456, 2020 View Details |
2020 | 37 | 69.9% |
|
Sudemycin E influences alternative splicing and changes chromatin modifications
Nucleic acids research 42 (8), 4947-4961, 2014 View Details |
2014 | 72 | 69.3% |
|
The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas
Acta neuropathologica communications 8, 1-8, 2020 View Details |
2020 | 36 | 69.2% |
|
Polyethyleneimine-mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina
BMC neuroscience 2, 1-8, 2001 View Details |
2001 | 99 | 68.9% |
|
Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes
Oncotarget 9 (98), 37112, 2018 View Details |
2018 | 50 | 68.6% |
|
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1
Acta neuropathologica 145 (1), 71-82, 2023 View Details |
2023 | 9 | 67.9% |
|
Intratumoral delivery of STING agonist results in clinical responses in canine glioblastoma
Clinical Cancer Research 27 (20), 5528-5535, 2021 View Details |
2021 | 25 | 67.8% |
|
Paradoxical relationship between degree of EGFR amplification and outcome in glioblastomas
The American journal of surgical pathology 36 (8), 1186, 2012 View Details |
2012 | 75 | 67.6% |
|
Reversible encephalopathy after cardiac transplantation: histologic evidence of endothelial activation, T-cell specific trafficking, and vascular endothelial growth factor expression
American journal of neuroradiology 30 (3), 588-590, 2009 View Details |
2009 | 82 | 67.5% |
|
CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion
Oncotarget 6 (30), 29675, 2015 View Details |
2015 | 60 | 66.4% |
|
CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Clinical Cancer Research 26 (16), 4390-4401, 2020 View Details |
2020 | 32 | 66.2% |
|
Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4
Cancer research 73 (2), 1011-1019, 2013 View Details |
2013 | 65 | 65.8% |
|
Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1-mutant gliomas
Clinical Cancer Research 25 (2), 747-759, 2019 View Details |
2019 | 37 | 65.2% |
|
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
Cancer Immunology, Immunotherapy 61, 789-801, 2012 View Details |
2012 | 67 | 64.9% |
|
SerpinB3 drives cancer stem cell survival in glioblastoma
Cell reports 40 (11), 2022 View Details |
2022 | 14 | 64.9% |
|
Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
The Journal of clinical investigation 133 (12), 2023 View Details |
2023 | 8 | 64.6% |
|
Systemic and local immunosuppression in patients with high-grade meningiomas
Cancer Immunology, Immunotherapy 68, 999-1009, 2019 View Details |
2019 | 36 | 64.4% |
|
A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.
Journal of Clinical Oncology 37 (15_suppl), 3012-3012, 2019 View Details |
2019 | 36 | 64.4% |
|
Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
Acta neuropathologica 124, 449-451, 2012 View Details |
2012 | 65 | 64.1% |
|
The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas
Archives of pathology & laboratory medicine 134 (8), 1170-1176, 2010 View Details |
2010 | 70 | 64.1% |
|
1p/19q testing has no significance in the workup of glioblastomas
Neuropathology and applied neurobiology 39 (6), 706-717, 2013 View Details |
2013 | 57 | 62.5% |
|
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies
Nature Reviews Rheumatology 8 (8), 448-457, 2012 View Details |
2012 | 59 | 61.7% |
|
Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity
Proceedings of the National Academy of Sciences 118 (9), e2015800118, 2021 View Details |
2021 | 20 | 61.6% |
|
Determining venous thromboembolism risk in patients with adult-type diffuse glioma
Blood, The Journal of the American Society of Hematology 141 (11), 1322-1336, 2023 View Details |
2023 | 7 | 60.9% |
|
Bone morphogenetic protein‐7 stimulates initial dendritic growth in sympathetic neurons through an intracellular fibroblast growth factor signaling pathway
Journal of neurochemistry 80 (1), 54-63, 2002 View Details |
2002 | 67 | 60.9% |
|
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13
Acta neuropathologica 143 (3), 403-414, 2022 View Details |
2022 | 12 | 60.4% |
|
Dendritic growth induced by BMP‐7 requires Smad1 and proteasome activity
Journal of neurobiology 48 (2), 120-130, 2001 View Details |
2001 | 62 | 59.5% |
|
YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas
International Journal of Clinical and Experimental Pathology 3 (3), 226, 2010 View Details |
2010 | 57 | 59.4% |
|
MNK inhibition disrupts mesenchymal glioma stem cells and prolongs survival in a mouse model of glioblastoma
Molecular Cancer Research 14 (10), 984-993, 2016 View Details |
2016 | 42 | 59.0% |
|
Differential response of glioma stem cells to arsenic trioxide therapy is regulated by MNK1 and mRNA translation
Molecular Cancer Research 16 (1), 32-46, 2018 View Details |
2018 | 32 | 56.8% |
|
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
Neuro-oncology 20 (9), 1197-1206, 2018 View Details |
2018 | 32 | 56.8% |
|
Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease
Acta Neuropathologica Communications 7, 1-19, 2019 View Details |
2019 | 27 | 56.4% |
|
Discovery of novel glioma serum biomarkers by proximity extension assay
Clinical Proteomics 20 (1), 12, 2023 View Details |
2023 | 6 | 56.2% |
|
Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression
JCI insight 7 (9), 2022 View Details |
2022 | 10 | 54.9% |
|
Telepathology for intraoperative neuropathologic consultations at an academic medical center: a 5-year report
Journal of Neuropathology & Experimental Neurology 66 (8), 750-759, 2007 View Details |
2007 | 49 | 54.9% |
|
BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine
Science translational medicine 12 (558), eaax2879, 2020 View Details |
2020 | 20 | 53.1% |
|
Cerebrospinal fluid contains biologically active bone morphogenetic protein-7
Experimental neurology 172 (2), 273-281, 2001 View Details |
2001 | 44 | 52.8% |
|
The Equivocally Amplified HER2 FISH Result on Breast Core Biopsy: Indications for Further Sampling Do Affect Patient Management
American journal of clinical pathology 129 (3), 383-390, 2008 View Details |
2008 | 44 | 52.7% |
|
PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis
JCI insight 7 (5), 2022 View Details |
2022 | 9 | 51.7% |
|
LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement
Neuro-oncology 22 (9), 1315-1326, 2020 View Details |
2020 | 19 | 51.6% |
|
The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction–based microsatellite loss of heterozygosity analysis of oligodendrogliomas
Journal of Neuropathology & Experimental Neurology 71 (1), 73-82, 2012 View Details |
2012 | 39 | 51.6% |
|
Surgical resection and adjuvant radiation therapy in the treatment of skull base chordomas
World neurosurgery 115, e13-e21, 2018 View Details |
2018 | 26 | 51.1% |
|
Neurological applications of belzutifan in von Hippel-Lindau disease
Neuro-oncology 25 (5), 827-838, 2023 View Details |
2023 | 5 | 50.7% |
|
Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma
PloS one 10 (8), e0134426, 2015 View Details |
2015 | 32 | 49.8% |
|
Impact of Morphology, MIB‐1, p53 and MGMT on Outcome in Pilocytic Astrocytomas
Brain pathology 20 (3), 581-588, 2010 View Details |
2010 | 37 | 49.6% |
|
The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
Neuro-oncology advances 3 (1), vdab085, 2021 View Details |
2021 | 13 | 48.8% |
|
Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer
Human pathology 57, 68-77, 2016 View Details |
2016 | 28 | 48.1% |
|
Identification and characterization of a novel indoleamine 2, 3-Dioxygenase 1 protein degrader for glioblastoma
Journal of Medicinal Chemistry 65 (23), 15642-15662, 2022 View Details |
2022 | 8 | 48.0% |
|
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin
Molecular carcinogenesis 56 (2), 325-336, 2017 View Details |
2017 | 25 | 47.5% |
|
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Nature medicine 25 (6), 1022-1022, 2019 View Details |
2019 | 19 | 46.8% |
|
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy
Immunotherapy 8 (9), 1059-1071, 2016 View Details |
2016 | 26 | 46.2% |
|
EGFR expression stratifies oligodendroglioma behavior
The American journal of pathology 179 (4), 1638-1644, 2011 View Details |
2011 | 31 | 46.0% |
|
Chordoid glioma: a case report and molecular characterization of five cases
Brain pathology 19 (3), 439-448, 2009 View Details |
2009 | 31 | 46.0% |
|
Comparison of telepathology systems in neuropathological intraoperative consultations
Neuropathology 29 (6), 655-663, 2009 View Details |
2009 | 31 | 46.0% |
|
Indoleamine 2, 3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer
Oncotarget 9 (34), 23482, 2018 View Details |
2018 | 21 | 45.4% |
|
Validation of whole genome methylation profiling classifier for central nervous system tumors
The Journal of Molecular Diagnostics 24 (8), 924-934, 2022 View Details |
2022 | 7 | 44.1% |
|
Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review
Neuro-oncology, noad059, 2023 View Details |
2023 | 4 | 43.7% |
|
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells
Acta neuropathologica 128, 723-732, 2014 View Details |
2014 | 25 | 42.8% |
|
Race influences survival in glioblastoma patients with KPS≥ 80 and associates with genetic markers of retinoic acid metabolism
Journal of neuro-oncology 142, 375-384, 2019 View Details |
2019 | 16 | 42.3% |
|
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors
Neuro-oncology 21 (9), 1164-1174, 2019 View Details |
2019 | 16 | 42.3% |
|
Application of telepathology for neuropathologic intraoperative consultations
Brain Pathology 19 (2), 317-322, 2009 View Details |
2009 | 24 | 41.2% |
|
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
Journal of Neuro-oncology 154 (2), 159-170, 2021 View Details |
2021 | 10 | 41.0% |
|
Proteasome inhibitors suppress formation of polyglutamine‐induced nuclear inclusions in cultured postmitotic neurons
Journal of neurochemistry 91 (5), 1044-1056, 2004 View Details |
2004 | 24 | 41.0% |
|
Potent Antineoplastic Effects of Combined PI3Kα–MNK Inhibition in Medulloblastoma
Molecular Cancer Research 17 (6), 1305-1315, 2019 View Details |
2019 | 15 | 40.7% |
|
Immunotherapy against gliomas: is the breakthrough near?
Drugs 79, 1839-1848, 2019 View Details |
2019 | 14 | 39.0% |
|
The essentials of molecular testing in CNS tumors: what to order and how to integrate results
Current neurology and neuroscience reports 20, 1-12, 2020 View Details |
2020 | 12 | 39.0% |
|
Longitudinal observational study of boxing therapy in Parkinson’s disease, including adverse impacts of the COVID-19 lockdown
BMC neurology 21 (1), 1-10, 2021 View Details |
2021 | 9 | 38.1% |
|
MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas
Neuro-oncology 23 (5), 858-860, 2021 View Details |
2021 | 9 | 38.1% |
|
Something old and something new about molecular diagnostics in gliomas
Surgical pathology clinics 5 (4), 919-939, 2012 View Details |
2012 | 21 | 37.9% |
|
Primary intracranial dural-based synovial sarcoma with an unusual SYT fluorescence in situ hybridization pattern: Case report
Journal of neurosurgery 109 (5), 897-903, 2008 View Details |
2008 | 20 | 37.5% |
|
Neuro-surgical considerations for treating IgG4-related disease with rare spinal epidural compression
Surgical Neurology International 9, 2018 View Details |
2018 | 15 | 37.2% |
|
Lgr5 marks post-mitotic, lineage restricted cerebellar granule neurons during postnatal development
PloS one 9 (12), e114433, 2014 View Details |
2014 | 19 | 37.0% |
|
Practical molecular diagnostics in neuropathology: making a tough job a little easier
Seminars in diagnostic pathology 27 (2), 105-113, 2010 View Details |
2010 | 19 | 36.5% |
|
The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results
Chin Clin Oncol 10 (4), 38, 2021 View Details |
2021 | 8 | 34.8% |
|
LNX1 modulates Notch1 signaling to promote expansion of the glioma stem cell population during temozolomide therapy in glioblastoma
Cancers 12 (12), 3505, 2020 View Details |
2020 | 10 | 34.4% |
|
NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy
bioRxiv, 2023 View Details |
2023 | 3 | 34.3% |
|
Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors
Acta Neuropathologica 145 (3), 365-367, 2023 View Details |
2023 | 3 | 34.3% |
|
Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas
Neuro-oncology 25 (3), 508-519, 2023 View Details |
2023 | 3 | 34.3% |
|
Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution
View Details |
2023 | 3 | 34.3% |
|
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
View Details |
2023 | 3 | 34.3% |
|
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Nature medicine 29 (12), 3067-3076, 2023 View Details |
2023 | 3 | 34.3% |
|
Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy
Journal of Clinical Medicine 11 (19), 5961, 2022 View Details |
2022 | 5 | 34.2% |
|
Response to BRAF/MEK inhibition after progression with BRAF inhibition in a patient with anaplastic pleomorphic xanthoastrocytoma
The Neurologist 23 (5), 163-166, 2018 View Details |
2018 | 13 | 33.9% |
|
Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients
Oral oncology 111, 104949, 2020 View Details |
2020 | 9 | 31.9% |
|
Therapeutic hypothesis testing with rodent brain tumor models
Neurotherapeutics 14, 385-392, 2017 View Details |
2017 | 12 | 30.8% |
|
Foreign body granuloma following orbital reconstruction with porous polyethylene
Ophthalmic Plastic & Reconstructive Surgery 32 (6), e137-e138, 2016 View Details |
2016 | 11 | 28.1% |
|
Clinical management of supratentorial non-skull base meningiomas
Cancers 14 (23), 5887, 2022 View Details |
2022 | 4 | 27.9% |
|
Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model
Epidemiology & Infection 145 (9), 1805-1814, 2017 View Details |
2017 | 10 | 27.5% |
|
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report
Journal of Clinical Neuroscience 64, 18-21, 2019 View Details |
2019 | 8 | 27.0% |
|
Characterization of squamous cell lung cancers from Appalachian Kentucky
Cancer Epidemiology, Biomarkers & Prevention 28 (2), 348-356, 2019 View Details |
2019 | 8 | 27.0% |
|
Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls
Acta Neuropathologica Communications 6, 1-9, 2018 View Details |
2018 | 9 | 26.9% |
|
How molecular testing can help (and hurt) in the workup of gliomas
American journal of clinical pathology 139 (3), 275-288, 2013 View Details |
2013 | 10 | 25.6% |
|
Molecular and clinical characterization of a recurrent cryptic unbalanced t (4q; 18q) resulting in an 18q deletion and 4q duplication
American Journal of Medical Genetics Part A 146 (22), 2898-2904, 2008 View Details |
2008 | 8 | 23.9% |
|
ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age—A report from the Children Oncology Group.
Journal of Clinical Oncology 35 (15_suppl), 10505-10505, 2017 View Details |
2017 | 8 | 23.9% |
|
TOP2B enzymatic activity on promoters and introns modulates multiple oncogenes in human gliomas
Clinical Cancer Research 27 (20), 5669-5680, 2021 View Details |
2021 | 5 | 23.6% |
|
CD11c+ CD163+ cells and signal transducer and activator of transcription 3 (STAT3) expression are common in melanoma leptomeningeal disease
Frontiers in immunology 12, 745893, 2021 View Details |
2021 | 5 | 23.6% |
|
Is next-generation sequencing alone sufficient to reliably diagnose gliomas?
Journal of Neuropathology & Experimental Neurology 79 (7), 763-766, 2020 View Details |
2020 | 6 | 23.3% |
|
Incidence of CNS tumors in Appalachian children
Journal of neuro-oncology 132, 507-512, 2017 View Details |
2017 | 7 | 21.8% |
|
Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing
Neuro-oncology advances 5 (1), vdad076, 2023 View Details |
2023 | 2 | 21.2% |
|
Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma
Nature Immunology 24 (10), 1654-1670, 2023 View Details |
2023 | 2 | 21.2% |
|
Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis
Neuro-oncology, noad065, 2023 View Details |
2023 | 2 | 21.2% |
|
From the ER to the OR: Initial Evaluation of Primary Central Nervous System Lymphoma
The neurologist 28 (3), 135-142, 2023 View Details |
2023 | 2 | 21.2% |
|
Modeling therapy-driven evolution of glioblastoma with patient-derived xenografts
Cancers 14 (22), 5494, 2022 View Details |
2022 | 3 | 20.7% |
|
Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma
Clinical Cancer Research 28 (14), 3156-3169, 2022 View Details |
2022 | 3 | 20.7% |
|
B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma
Diagnostic pathology 13 (1), 1-6, 2018 View Details |
2018 | 6 | 20.4% |
|
Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient
Neuro-Oncology Advances 3 (1), vdab045, 2021 View Details |
2021 | 4 | 19.1% |
|
A 10‐YEAR OLD GIRL WITH NECK PAIN
Brain Pathology 20 (2), 519, 2010 View Details |
2010 | 5 | 17.0% |
|
Clinical utility of GlioSeq next-generation sequencing test in pediatric and young adult patients with brain tumors
Journal of Neuropathology & Experimental Neurology 78 (8), 694-702, 2019 View Details |
2019 | 4 | 15.9% |
|
Low‐grade recurrence of a congenital high‐grade supratentorial tumor with astrocytic features in the absence of adjuvant therapy
Neuropathology 31 (3), 286-291, 2011 View Details |
2011 | 4 | 14.5% |
|
Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma
Neuro-oncology advances 2 (1), vdz057, 2020 View Details |
2020 | 3 | 12.4% |
|
Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma.
Journal of Clinical Oncology 40 (16_suppl), 2016-2016, 2022 View Details |
2022 | 2 | 11.9% |
|
The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
PloS one 17 (2), e0257725, 2022 View Details |
2022 | 2 | 11.9% |
|
Differences in molecular profiles of glioblastomas according to location
Neuro-oncology 21 (1), 4-5, 2019 View Details |
2019 | 2 | 7.3% |
|
Rapid development of an aneurysm at the anastomotic site of a superficial temporal artery to middle cerebral artery bypass: case report and literature review
World neurosurgery 128, 314-319, 2019 View Details |
2019 | 2 | 7.3% |
|
Dipg-33. New Therapeutic Approach for Brainstem Glioma: Intranasal Delivery of Nanoliposomal Sn-38
Neuro-oncology 20 (suppl_2), i55-i55, 2018 View Details |
2018 | 2 | 6.9% |
|
Chordoid glioma: Molecular characterization of four cases
Laboratory Investigation 88, 321A-321A, 2008 View Details |
2008 | 2 | 6.8% |
|
PDTM-28. TARGETED INHIBITION OF EZH2 AND BET BROMODOMAIN PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS
Neuro-Oncology 19 (suppl_6), vi196-vi196, 2017 View Details |
2017 | 2 | 6.7% |
|
Prospective comparison of FISH versus PCR-based microsatellite LOH in the evaluation of gliomas for 1p/19q codeletion
Journal of Neuropathology and Experimental Neurology 70 (6), 526-526, 2011 View Details |
2011 | 2 | 6.7% |
|
A 29 year old woman with acute mental status changes
Brain Pathology 23 (4), 479, 2013 View Details |
2013 | 2 | 6.6% |
|
CSIG-08. A REGULATORY CIRCUIT OF miR-125b/miR-20b AND Wnt SIGNALING CONTROLS GBM PHENOTYPES THROUGH FZD6-MEDIATED PATHWAYS
Neuro-Oncology 18 (suppl_6), vi42-vi42, 2016 View Details |
2016 | 2 | 6.4% |
|
Mutant idh1 suppresses apoptosis regulator par-4 in gliomas
Neuro-oncology 16 (Suppl 3), iii6, 2014 View Details |
2014 | 2 | 6.3% |
|
Histology trumps apparent 1P/19Q codeletion in glioblastomas
Journal of Neuropathology and Experimental Neurology 71 (6), 548-548, 2012 View Details |
2012 | 2 | 6.3% |
|
Factors associated with nuclear localization of the ire isoform of dmt1 (nramp2/dct1)
Blood 96 (11 PART I), 2000 View Details |
2000 | 1 | 0.0% |
|
Post-therapeutic changes in the molecular profile of glioblastomas
Journal of Clinical Oncology 27 (15_suppl), 2026-2026, 2009 View Details |
2009 | 1 | 0.0% |
|
Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer.
Journal of Clinical Oncology 33 (15_suppl), 532-532, 2015 View Details |
2015 | 1 | 0.0% |
|
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma
Neuro-oncology 17 (3), 478-479, 2015 View Details |
2015 | 1 | 0.0% |
|
Cbio-07. Lipid droplets, A novel diagnostic biomarker and metabolic target in glioblastoma
Neuro-Oncology 18 (suppl_6), vi36-vi36, 2016 View Details |
2016 | 1 | 0.0% |
|
Path-44. race influences patient survival in glioma and associates with genetic markers of retinoic acid metabolism
Neuro-oncology 19 (Suppl 6), vi180, 2017 View Details |
2017 | 1 | 0.0% |
|
Nuclear localization of immunosuppressive IDO1 in cancer: a paradigm‐shift to the tryptophan depletion theory
The FASEB Journal 31, 747.4-747.4, 2017 View Details |
2017 | 1 | 0.0% |
|
Tmic-45. Diffusion Of D-2-hydroxyglutarate From Idh1 Mutant Gliomas In The Brain
Neuro-oncology 19 (Suppl 6), vi253, 2017 View Details |
2017 | 1 | 0.0% |
|
218 divergent clonal evolution of melanoma brain metastases in response to immunotherapy
Neurosurgery 65 (CN_suppl_1), 121-122, 2018 View Details |
2018 | 1 | 0.0% |
|
MBCL-08. Molecular characterization of nodular desmoplastic medulloblastomas in young children treated on ACNS1221. A report from the Children Oncology Group
Neuro-Oncology 20 (suppl_2), i118-i119, 2018 View Details |
2018 | 1 | 0.0% |
|
4. Molecular characterizations of adult diffuse gliomas by the Oncoscan CNV Plus assay and next-generation sequencing (NGS)
Cancer Genetics 233, S2, 2019 View Details |
2019 | 1 | 0.0% |
|
Integrin α6β4 is downregulated in mutant IDH1 oligodendrogliomas, promotes glioma growth, and associates with a worse outcome in glioma patients
bioRxiv, 726489, 2019 View Details |
2019 | 1 | 0.0% |
|
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma (vol 25, pg 462, 2019)
Nature medicine 25 (6), 1022-1022, 2019 View Details |
2019 | 1 | 0.0% |
|
STEM-06. tissue factor signaling in glioblastoma tumor-initiating cells
Neuro-Oncology 21 (Suppl 6), vi234, 2019 View Details |
2019 | 1 | 0.0% |
|
Mesenchymal stemlike cells in glioblastoma
Neuro-oncology 22 (10), 1409-1410, 2020 View Details |
2020 | 1 | 0.0% |
|
Intraventricular adult Taenia solium causing hydrocephalus: a case report
Surgical Neurology International 11, 2020 View Details |
2020 | 1 | 0.0% |
|
A New Mouse Model of Diffuse Midline Glioma to Test Targeted Immunotherapies
bioRxiv, 2021.10. 15.464284, 2021 View Details |
2021 | 1 | 0.0% |
|
CRISPR-Cas9 Screen Reveals PSMB3 Contributes to Gliomagenesis Through Proteasome-Dependent and Independent Mechanisms
bioRxiv, 2021.07. 28.453566, 2021 View Details |
2021 | 1 | 0.0% |
|
Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation
Journal of Neuropathology & Experimental Neurology 81 (3), 239-241, 2022 View Details |
2022 | 1 | 0.0% |
|
Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma
Journal of Neuro-Oncology 158 (3), 331-339, 2022 View Details |
2022 | 1 | 0.0% |
|
Methylation profiling improves the care of pediatric brain tumor patients
AJSP: Reviews & Reports 27 (3), e1-e4, 2022 View Details |
2022 | 1 | 0.0% |
|
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas
Nature communications 14 (1), 6279, 2023 View Details |
2023 | 1 | 0.0% |
|
Deep intravital brain tumor imaging enabled by tailored three-photon microscopy and analysis
bioRxiv, 2023.06. 17.545350, 2023 View Details |
2023 | 1 | 0.0% |
|
Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma
Antioxidants & Redox Signaling 39 (13-15), 923-941, 2023 View Details |
2023 | 1 | 0.0% |
|
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
Clinical Cancer Research 29 (23), 4973-4989, 2023 View Details |
2023 | 1 | 0.0% |
|
Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review
Cancers 15 (14), 3655, 2023 View Details |
2023 | 1 | 0.0% |
|
LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression
Research Square, 2023 View Details |
2023 | 1 | 0.0% |
|
Glioma Response to IDH Inhibition: Real-World Experience
Clinical Cancer Research 29 (23), 4709-4710, 2023 View Details |
2023 | 1 | 0.0% |
|
Ros1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients
Modern Pathology 36 (11), 100294, 2023 View Details |
2023 | 1 | 0.0% |